Recent News

Potential Assays for Pinpointing Ovarian, Endometrial Cancers

Do Patients With Low-Grade Serous Ovarian Carcinoma Benefit From Targeted Sequencing?

‘Sticky Webs of DNA’ in Pathogenesis of Ovarian Cancer

FDA Approves Olaparib for First-Line Maintenance of BRCA-Mutated, Advanced Ovarian Cancer

Novel Vascular Technique Being Studied in Advanced Ovarian Cancer

Shedding Light on Resistance to PARP Inhibitors in Patients With Ovarian Cancer

NICE Rejects Olaparib Tablets in Ovarian Cancer Maintenance Therapy

Durvalumab Plus Olaparib in BRCA-Mutant Ovarian Cancer

Apatinib After Second-Line Chemotherapy Failure in Advanced Ovarian Cancer

ESMO 2018: Doxorubicin vs. Gemcitabine in Bevacizumab-Based Therapy for Ovarian Cancer

Priority Review Granted by FDA to Olaparib Maintenance Therapy for Some Patients With Ovarian Cancer

ESMO 2018: Novel Combination Therapy for Platinum-Resistant Ovarian Cancer

ESMO 2018: Early Results With Oregovomab/Nivolumab in Recurrent Ovarian Cancer

ESMO 2018: Niraparib in Resistant Subsets of Ovarian Cancer

ESMO 2018: New Compound Active in Treatment of Platinum-Resistant Ovarian Cancer

ESMO 2018: ‘Outstanding’ Results With Olaparib Maintenance in Advanced Ovarian Cancer

Novel Angiogenic Target to Combat Adaptive Resistance

Immunotherapy Combination Active in Ovarian Cancer

International Cancer Immunotherapy Conference: Early Study Results of Vaccine in HER2-Positive Cancers

Ovarian Cancer Research Symposium: Stromal Cell Expression and Metastasis

Ovarian Cancer Research Symposium: Heterogeneity of Cancer-Associated Fibroblasts

Ovarian Cancer Research Symposium: Role of Antiapoptotic Genes in Chemotherapy Resistance

Ovarian Cancer Research Symposium: Acquired Resistance to PARP Inhibitors

Ovarian Cancer Research Symposium: Is ATR Worthy Target in Resistant Disease?

Ovarian Cancer Research Symposium: Early Results With Immunotherapy Combination

Ovarian Cancer Research Symposium: Biomarkers for Early Detection

Phase II Trial Answers Bevacizumab + Everolimus Question in Resistant Ovarian Cancer

Can m-TORC1/2 Inhibitor Added to Chemotherapy Improve Outcomes in Ovarian Cancer?

Combination of Apatinib and Oral Etoposide in Resistant Ovarian Cancer

Shedding New Light on Resistance to PARP Inhibitors in Ovarian Cancer

Does Fertility Treatment Increase Risk of Ovarian Cancer?

FDA Grants Fast Track Designation to AVB-S6-500 for Recurrent Ovarian Cancer

Preclinical Study Focuses on Metastatic Process in High-Grade Ovarian Cancer

Breakthrough Device Designation Granted by FDA to Liquid Biopsy

Mirvetuximab Soravtansine Plus Bevacizumab in Platinum-Resistant Ovarian Cancer

Secondary Cytoreductive Surgery for Epithelial Ovarian Cancer

Does Olaparib Increase the Risk of MDS/AML in Patients Treated for Relapsed Ovarian Cancer?

ESHRE 2018: Early-Stage Research on Artificial Ovary for Fertility Preservation